Granulomatosis With Polyangiitis
Conditions
Brief summary
The aim of this study is to identify the optimal maintenance therapy for granulomatosis with polyangiitis (GPA) by comparing the MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in preventing relapses.
Detailed description
Granulomatosis with polyangiitis (GPA), a systemic small-vessel vasculitis, could involve multiple tissues and organs. Remission of GPA can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent and remain a challenge. The optimal drug for maintenance treatment is not determined. Tofacitinib is a Jak inhibitor which has been proved to be effective in multiple inflammatory diseases such as rheumatoid arthritis. But the efficiency and safety of tofacitinib in treating GPA remains unclear yet. In the present randomized trial, the comparison of MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in preventing relapses will be conducted.
Interventions
DRUGTofacitinib
1. Tofacitinib 5mg twice a day for 12months; 2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
DRUGMethotrexate
1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week) 2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with newly diagnosed or relapsing Granulomatosis with polyangiitis met the criteria of 1990 ACR and 2012 Chapel Hill criteria 2. Patients in disease flare have achieved remission using a treatment combining corticosteroids and IV cyclophosphamide 3. Remission is defined as a Birmingham Vasculitis Activity/ Wegener's granulomatosis (BVAS/WG) score of 0 and receiving 10 mg/day of oral prednisone (or equivalent) at least 2 weeks 4. Age 18 to 75 years 5. Written informed consent obtained before taking part in the study
Exclusion criteria
1. Severe GPA defined as potentially organ- or life-threatening disease (i.e. alveolar haemorrhage, heart failure caused by myocarditis or pericarditis, progressive neurological symptoms, deaf, blindness, et al.) 2. Serum creatinine\>120umol/L or proteinuria\>1.0g/d 3. Failure to response after treatment with methotrexate or cyclophosphamide previously 4. Receipt of a JAKi therapy previously 5. Co-existence of another systemic autoimmune disease 6. Secondary vasculitis (following neoplastic disease, an infection or antithyroid drugs) 7. Malignancy or history of malignancy 8. Infection by HIV, HCV, HBV or tuberculosis 9. Severe uncontrolled cardiovascular, pulmonary, liver, gastrointestinal, endocrine, hematological, neurological, or psychiatric diseases that are not related to systemic vasculitis 10. Allergic to any of the medication (cyclophosphamide, corticosteroids, tofacitinib, methotrexate) 11. Blood dyscrasias including confirmed: Hemoglobin \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; Absolute neutrophil count \<1.5 x 109/L; Platelet count \<100 x 109/L; Alanine transaminase or aspartate aminotransferase or total bilirubin\>1.5 upper normal limit; Estimated glomerular filtration rate\<60ml/min/1.73m2 12. Any medical or psychiatric disorder which, in the investigator's opinion, may prevent the administration of treatment and patient follow-up according to the protocol, and/or which may expose the patient to a too greater risk of an adverse effect. 13. Incapacity or refusal to understand or sign the informed consent form. 14. Pregnancy, breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse rate (major or minor) at 12 months | From the enrollment to the the end of 12 month. | The major or minor relapse rate equals to the patients with relapse/ total participants ( A major relapse should be defined as the re-occurrence or new onset of potentially organ- or life-threatening disease activity that cannot be treated with an increase of GC alone and requires further escalation of treatment. All other relapses should be classified as minor.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first relapse. | From the enrollment to the the end of 12 month. | The time period from the baseline to the time when the first relapse occurred. |
| Number of relapse | From the enrollment to the the end of 12 month. | Total times of relapse during the whole period of 12-month follow-up. |
| Cumulative dosage of corticosteroids | From the enrollment to the the end of 12 month. | The cumulative dosage of corticosteroids during the whole period of 12-month follow-up. The cumulative dosage = Sum of different dose of prednisone every day. |
| Adverse events | From the enrollment to the the end of 12 month. | All the kinds of adverse event related to the treatment and the disease itself will be recorded. |
Countries
China
Contacts
Primary ContactLindi Jiang, PhD
Backup ContactYun Liu, PhD
Outcome results
None listed